Abnova (Taiwan) Corporation (TPE:4133)

Market Cap	1.54B -15.9%
Revenue (ttm)	355.40M -1.6%
Net Income	1.80M -96.9%
EPS	0.03 -96.9%
Shares Out	60.55M
PE Ratio	852.80
Forward PE	n/a
Dividend	0.90 (3.56%)
Ex-Dividend Date	Jun 16, 2025

Volume	200,764
Average Volume	565,521
Open	25.05
Previous Close	25.25
Day's Range	24.85 - 25.45
52-Week Range	21.70 - 35.10
Beta	0.50
RSI	52.61
Earnings Date	Feb 26, 2026

About Abnova (Taiwan)

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4133

Financial Performance

In 2024, Abnova (Taiwan)'s revenue was 355.26 million, a decrease of -7.01% compared to the previous year's 382.05 million. Earnings were 61.61 million, an increase of 41.05%.